Bicara Therapeutics names Cohlhepp CEO effective January 2027; Q2 net loss $55.4 million
Bicara Therapeutics said Ryan Cohlhepp, its President and Chief Operating Officer, will succeed Claire Mazumdar as Chief Executive Officer effective January 1, 2027, and Jenn Larson will become Chief Financial Officer effective August 12, 2026. The company also reported a second quarter 2026 net loss of $55.4 million, up from $27.4 million a year earlier, while cash, cash equivalents and marketable securities rose to $497.3 million.
Key points
- Ryan Cohlhepp will become CEO effective January 1, 2027; Claire Mazumdar will become Vice Chair of the Board and Strategic Advisor.
- Jenn Larson, CPA, appointed Chief Financial Officer effective August 12, 2026, succeeding Ivan Hyep.
- Q2 2026 net loss was $55.4 million versus $27.4 million in Q2 2025; R&D expenses were $45.8 million versus $24.8 million.
- Cash, cash equivalents and marketable securities were $497.3 million at June 30, 2026, which the company expects to fund operations into the first half of 2029.
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.